| Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy (NCT03226717) | Assiut University | 2017-08-10 |
| HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment (NCT03524794) | University College, London | 2017-08-08 |
| Expanding the Pool in Orthotopic Heart Transplantation (NCT03222531) | Mary E. Keebler, MD | 2017-08-01 |
| Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1 (NCT03245931) | TriHealth Inc. | 2017-07-20 |
| Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID) (NCT03214679) | City University of New York, School of Public Health | 2017-07-20 |
| HCV RAS Testing in Public Health Programs (NCT04242433) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2017-07-16 |
| A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection (NCT03253471) | Alios Biopharma Inc. | 2017-07-07 |
| Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC) Pilot Study (NCT03231930) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 2017-06-29 |
| Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD (NCT03973502) | National Taiwan University Hospital | 2017-06-12 |
| Project I Test: Implementing HIV Testing in Opioid Treatment Programs (NCT03135886) | Columbia University | 2017-06-12 |
| Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic (NCT03831555) | Emory University | 2017-06-05 |
| Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease (NCT03145623) | University Hospital, Toulouse | 2017-06-02 |
| Hepatitis c and Vitamin D and Iron Status (NCT03166280) | Eman Sayed Hassan Abd Allah | 2017-06-01 |
| Maraviroc Efficacy for Hepatitis C (NCT02881762) | University of Maryland, Baltimore | 2017-06-01 |
| Identification to Elimination in HCV-Infected Individuals (NCT03195205) | TruCare Internal Medicine & Infectious Disease | 2017-06-01 |
| Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care (NCT03093415) | Oregon Health and Science University | 2017-05-30 |
| Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures (NCT05361603) | University Hospital, Limoges | 2017-05-24 |
| Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers (NCT03038763) | University of Pennsylvania | 2017-05-11 |
| Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial (NCT03032666) | Ala'a Sharara | 2017-05-01 |
| Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs (NCT02940691) | Kirby Institute | 2017-05-01 |
| Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (NCT02897596) | Fundacion Clinic per a la Recerca Biomédica | 2017-04-28 |
| Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens (NCT03366610) | Bristol-Myers Squibb | 2017-04-28 |
| Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects (NCT03092375) | University of Florida | 2017-04-20 |
| Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France (NCT02959684) | University Paris 7 - Denis Diderot | 2017-04-14 |
| Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention (NCT02970136) | University of Miami | 2017-04-11 |
| A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection (NCT03099135) | Janssen Research & Development, LLC | 2017-04-10 |
| Direct Acting Agents in Hepatitis C Patients (NCT03145844) | Fehmi Tabak | 2017-04-09 |
| Pilot Study of HIV and Hepatitis B and C Screening in Surgery (NCT03088995) | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | 2017-04-01 |
| Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort (NCT03111966) | Hepa C | 2017-03-31 |
| Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (NCT02625909) | Kirby Institute | 2017-03-09 |
| Transplanting Hepatitis C Positive Organs (NCT03086044) | Brigham and Women's Hospital | 2017-03-01 |
| Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients (NCT03061032) | Iran Hepatitis Network | 2017-03-01 |
| Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir (NCT03247296) | MTI University | 2017-02-28 |
| Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals (NCT02933970) | Andrew Talal | 2017-02-28 |
| HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention (NCT03242655) | Montefiore Medical Center | 2017-02-21 |
| Epidemiology of Chronic Hepatitis C and Disease Modelling (NCT03566563) | Changi General Hospital | 2017-02-21 |
| The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID (NCT02971488) | Hospital Universitario Infanta Leonor | 2017-01-15 |
| Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response (NCT03254121) | Karolinska Institutet | 2017-01-01 |
| Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C (NCT03402165) | Sherief Abd-Elsalam | 2017-01-01 |
| Project MATLINK: Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community (NCT04947475) | Yale University | 2017-01-01 |
| Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients (NCT03587714) | Assiut University | 2017-01-01 |
| Accelerated Pre-treatment Evaluation for HCV Infected Persons Who Inject Drugs (NCT02755402) | Centre hospitalier de l'Université de Montréal (CHUM) | 2017-01-01 |
| A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C Treatment & HIV Viral Suppression (NCT02772328) | Johns Hopkins Bloomberg School of Public Health | 2016-12-19 |
| Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel (NCT03144440) | Carmel Medical Center | 2016-12-13 |
| Testing and Treating Hepatitis C in Community Pharmacies (NCT02706223) | University of Dundee | 2016-12-01 |
| Eliminate Hepatitis C/EC Partnership Evaluation Protocol (NCT04061551) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 2016-12-01 |
| Advanced Electronic Population Health and Personal Health Record Tools to Improve Once Lifetime Hepatitis C Screening (NCT03654365) | MetroHealth Medical Center | 2016-11-17 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) (NCT02956629) | Merck Sharp & Dohme LLC | 2016-11-16 |
| Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs (NCT02347345) | Rockefeller University | 2016-11-15 |
| Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV (NCT03004625) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2016-11-01 |
| Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening (NCT02833298) | Icahn School of Medicine at Mount Sinai | 2016-11-01 |
| DRug Use and Infections in Hai Phong ViEtnam Among Persons Who Inject Drugs (NCT03526939) | New York University | 2016-10-17 |
| Anticipated and Perceived Benefits Following Hepatitis C Treatment (NCT03000023) | University of North Carolina, Chapel Hill | 2016-10-01 |
| Patient-Centered Models of HCV Care for People Who Inject Drugs (NCT02824640) | Prisma Health-Upstate | 2016-09-15 |
| Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients (NCT03200184) | Tehran University of Medical Sciences | 2016-09-01 |
| Strategic Transformation of the Market of HCV Treatments (NCT02961426) | Drugs for Neglected Diseases | 2016-09-01 |
| Integrating HCV and HIV Screening During the Era of HIV Antigen Testing (NCT02869776) | Boston Medical Center | 2016-09-01 |
| PoC-HCV Genedrive Viral Detection Assay Validation Study (NCT02992184) | ANRS, Emerging Infectious Diseases | 2016-09-01 |
| Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 (NCT02705534) | Tehran University of Medical Sciences | 2016-09-01 |
| Study of Hepatitis C Treatment During Pregnancy (NCT02683005) | Catherine Chappell | 2016-09-01 |
| A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection (NCT03186313) | Egyptian Liver Hospital | 2016-09-01 |
| Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (NCT02533934) | University of California, San Francisco | 2016-08-01 |
| Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients (NCT02781649) | Johns Hopkins University | 2016-07-20 |
| Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas (NCT02762448) | Tainan Municipal Hospital | 2016-07-01 |
| Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) (NCT02745132) | Instituto de Investigación Marqués de Valdecilla | 2016-06-01 |
| Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence (NCT03197155) | Hospices Civils de Lyon | 2016-06-01 |
| Hepatitis C Screening in the Primary Care Setting (NCT03316313) | New York Institute of Technology | 2016-06-01 |
| LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients (NCT02631772) | Medical University of South Carolina | 2016-06-01 |
| Swiss HCVree Trial (NCT02785666) | University of Zurich | 2016-06-01 |
| Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) (NCT02768961) | Instituto de Investigación Marqués de Valdecilla | 2016-05-10 |
| Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV. (NCT03775798) | Austral University, Argentina | 2016-05-01 |
| Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis (NCT02732405) | Istituto Clinico Humanitas | 2016-05-01 |
| Dynamic Liver Tests in Liver Disease (NCT02782247) | Queen Mary University of London | 2016-05-01 |
| A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar (NCT03205618) | Bristol-Myers Squibb | 2016-04-26 |
| Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals (NCT02786758) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 2016-04-01 |
| A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects (NCT02760758) | Cocrystal Pharma, Inc. | 2016-04-01 |
| A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use (NCT02336139) | Kirby Institute | 2016-03-16 |
| A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection (NCT02673489) | Bristol-Myers Squibb | 2016-03-15 |
| The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital (NCT02555475) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 2016-03-01 |
| Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR (NCT02669966) | University of Florida | 2016-03-01 |
| Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection (NCT02836925) | Fondazione Italiana Linfomi - ETS | 2016-03-01 |
| 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (NCT02605304) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2016-02-17 |
| Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers (NCT02404805) | University of Colorado, Denver | 2016-02-01 |
| Chronic Hepatitis B and C Recall Northern Holland (NCT02687061) | Stichting MDL Holland-Noord | 2016-02-01 |
| Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia (NCT02825212) | Icahn School of Medicine at Mount Sinai | 2016-02-01 |
| Evaluation of HepCure Toolkit to Improve Harvoni Adherence (NCT02740556) | Icahn School of Medicine at Mount Sinai | 2016-02-01 |
| The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure (NCT02580474) | Myeong Jun Song | 2016-02-01 |
| Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV (NCT02600325) | Erasmus Medical Center | 2016-02-01 |
| Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) (NCT02661126) | Merck Sharp & Dohme LLC | 2016-01-19 |
| EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients (NCT02652377) | Enanta Pharmaceuticals, Inc | 2016-01-10 |
| Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) (NCT02601573) | Merck Sharp & Dohme LLC | 2016-01-05 |
| A Drug-drug Interaction Study Between Daclatasvir and Metformin (NCT02565862) | Radboud University Medical Center | 2016-01-01 |
| Improving Fibrosis Outcomes With Metformin (NCT02306070) | Ottawa Hospital Research Institute | 2016-01-01 |
| Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes (NCT02650024) | University of California, San Diego | 2016-01-01 |
| The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital (NCT02904252) | Mahidol University | 2016-01-01 |
| Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir (NCT02647632) | ANRS, Emerging Infectious Diseases | 2016-01-01 |
| Treatment as Prevention for Hepatitis C in Iceland (NCT02647879) | Landspitali University Hospital | 2016-01-01 |
| Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures (NCT02646111) | Tel-Aviv Sourasky Medical Center | 2016-01-01 |
| Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia (NCT02628691) | Institute of Tropical Medicine, Belgium | 2015-12-17 |
| Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (NCT02402699) | Bristol-Myers Squibb | 2015-12-15 |